RCKT
Price:
$14.11
Market Cap:
$1.29B
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated ...[Read more]
Industry
Biotechnology
IPO Date
2015-02-18
Stock Exchange
NASDAQ
Ticker
RCKT
According to Rocket Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.25B. This represents a change of -43.86% compared to the average of 2.22B of the last 4 quarters.
The mean historical Enterprise Value of Rocket Pharmaceuticals, Inc. over the last ten years is 960.28M. The current 1.25B Enterprise Value has changed 12.88% with respect to the historical average. Over the past ten years (40 quarters), RCKT's Enterprise Value was at its highest in in the December 2020 quarter at 2.79B. The Enterprise Value was at its lowest in in the March 2015 quarter at -2859559.76.
Average
960.28M
Median
745.61M
Minimum
41.45M
Maximum
2.80B
Discovering the peaks and valleys of Rocket Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.14%
Maximum Annual Enterprise Value = 2.80B
Minimum Annual Increase = -77.25%
Minimum Annual Enterprise Value = 41.45M
Year | Enterprise Value | Change |
---|---|---|
2023 | 2.49B | 104.51% |
2022 | 1.22B | 3.90% |
2021 | 1.17B | -58.23% |
2020 | 2.80B | 186.60% |
2019 | 977.54M | 90.31% |
2018 | 513.67M | 1.14% |
2017 | 41.45M | -77.25% |
2016 | 182.25M | 43.02% |
2015 | 127.43M | 49.01% |
2014 | 85.51M | 92.19% |
The current Enterprise Value of Rocket Pharmaceuticals, Inc. (RCKT) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
1.62B
5-year avg
1.73B
10-year avg
960.28M
Rocket Pharmaceuticals, Inc.’s Enterprise Value is greater than uniQure N.V. (97.71M), less than Rhythm Pharmaceuticals, Inc. (3.64B), greater than Solid Biosciences Inc. (176.48M), greater than MeiraGTx Holdings plc (427.31M), less than Vaxcyte, Inc. (10.01B), greater than Larimar Therapeutics, Inc. (363.34M), greater than Syndax Pharmaceuticals, Inc. (1.24B), less than Merus N.V. (2.68B), greater than Sutro Biopharma, Inc. (57.26M), greater than Stoke Therapeutics, Inc. (457.69M), greater than Pliant Therapeutics, Inc. (770.48M), less than Dyne Therapeutics, Inc. (2.51B), less than Cytokinetics, Incorporated (6.54B), less than Revolution Medicines, Inc. (9.43B), greater than REGENXBIO Inc. (502.58M), greater than Day One Biopharmaceuticals, Inc. (963.46M), greater than Replimune Group, Inc. (984.10M), less than Mirum Pharmaceuticals, Inc. (2.24B), less than Viridian Therapeutics, Inc. (1.42B), greater than Inozyme Pharma, Inc. (202.73M),
Company | Enterprise Value | Market cap |
---|---|---|
97.71M | $281.74M | |
3.64B | $3.68B | |
176.48M | $216.15M | |
427.31M | $463.45M | |
10.01B | $11.04B | |
363.34M | $393.05M | |
1.24B | $1.37B | |
2.68B | $3.11B | |
57.26M | $206.97M | |
457.69M | $605.41M | |
770.48M | $789.88M | |
2.51B | $3.02B | |
6.54B | $5.79B | |
9.43B | $9.55B | |
502.58M | $475.14M | |
963.46M | $1.38B | |
984.10M | $1.02B | |
2.24B | $2.15B | |
1.42B | $1.60B | |
202.73M | $180.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rocket Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rocket Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Rocket Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Rocket Pharmaceuticals, Inc. (RCKT)?
What is the 3-year average Enterprise Value for Rocket Pharmaceuticals, Inc. (RCKT)?
What is the 5-year average Enterprise Value for Rocket Pharmaceuticals, Inc. (RCKT)?
How does the current Enterprise Value for Rocket Pharmaceuticals, Inc. (RCKT) compare to its historical average?